top of page
The Sound of Evolution
Finasteride
Mechanism of action:
Finasteride is a 5α-reductase inhibitor. 5α-reductase is responsible for converting testosterone into dihydrotestosterone. After binding to this enzyme, finasteride significantly reduces the production of dihydrotestosterone, thereby lowering dihydrotestosterone-mediated growth signaling in prostate tissue.
Reference(s):
1. Smith AB et al. (2009). Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag.
2. Agamia NF et al. (2016). Benign prostatic hyperplasia, metabolic syndrome and androgenic alopecia: Is there a possible relationship? Arab J Urol.
3. Vaughan ED et al. (2003). Long-term experience with 5-alpha-reductase inhibitors. Rev Urol.
bottom of page